Nexalin Technology, Inc.(NXL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NXL Nexalin Technology, Inc.

Post-Mkt 12-23 17:33:05 EST

0.7200

-0.0502

-6.52%

盘后0.7200

+0.00000.00%

17:17 EST

High0.8200	Low0.7151	Vol250.22K
Open0.7703	D1 Closing0.7702	Amplitude13.62%
Mkt Cap13.43M	Tradable Cap11.14M	Total Shares18.65M
T/O190.44K	T/O Rate1.62%	Tradable Shares15.47M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NXL","market":"US","secType":"STK","nameCN":"Nexalin Technology, Inc.","latestPrice":0.72,"timestamp":1766523600000,"preClose":0.7702,"halted":0,"volume":250223,"hourTrading":{"tag":"盘后","latestPrice":0.72,"preClose":0.72,"latestTime":"17:17 EST","volume":842,"amount":606.19601392,"timestamp":1766528244421},"delay":0,"floatShares":15469100,"shares":18651939,"eps":-0.599183,"marketStatus":"Post-Mkt","change":-0.0502,"latestTime":"12-23 17:33:05 EST","open":0.7703,"high":0.82,"low":0.7151,"amount":190438.51976959998,"amplitude":0.136198,"askPrice":0.757,"askSize":100,"bidPrice":0.711,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.599183,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766538000000},"marketStatusCode":4,"adr":0,"listingDate":1663300800000,"exchange":"NASDAQ","adjPreClose":0.7702,"preHourTrading":{"tag":"盘前","latestPrice":0.8,"preClose":0.7702,"latestTime":"08:00 EST","volume":49,"amount":39.2,"timestamp":1766494800269},"postHourTrading":{"tag":"盘后","latestPrice":0.72,"preClose":0.72,"latestTime":"17:17 EST","volume":842,"amount":606.19601392,"timestamp":1766528244421},"volumeRatio":1.401233},"requestUrl":"/m/hq/s/NXL/tweets","defaultTab":"tweets","newsList":[{"id":"2588460740","title":"Nexalin Advances Non-Invasive Alzheimer's Therapy Toward FDA Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2588460740","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588460740?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:03","pubTimestamp":1764767039,"startTime":"0","endTime":"0","summary":"Nexalin Technology Inc. has announced progress in its research and development efforts for the treatment of Alzheimer's disease. The company recently held a Q-Sub meeting with the FDA, during which they discussed Nexalin's existing clinical data and plans for new U.S.-based pilot studies, followed by a large pivotal study to assess the safety and efficacy of the Gen-2 SYNC console in patients with mild to moderate Alzheimer's disease. Key aspects such as patient population, dosing paradigm, and statistical analysis were aligned upon, and appropriate clinical endpoints were reviewed. The results of these studies have not yet been presented, as Nexalin is currently incorporating FDA feedback into its final pilot study protocol and will provide updates on clinical milestones as appropriate.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL2W8DgN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","NXL"],"gpt_icon":0},{"id":"2588767046","title":"Nexalin Technology Inc - Potential De Novo Pathway Discussed for Nexalin's Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2588767046","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588767046?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:01","pubTimestamp":1764766860,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X90EU:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NXL"],"gpt_icon":0},{"id":"2588504679","title":"Nexalin Technology Inc - Reviewed Endpoints for Alzheimer's Outcomes Including Cognitive Assessments","url":"https://stock-news.laohu8.com/highlight/detail?id=2588504679","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588504679?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:01","pubTimestamp":1764766860,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X90EU:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NXL"],"gpt_icon":0},{"id":"2588046761","title":"Nexalin Technology Inc - Plans U.S. Pilot and Pivotal Studies for Gen-2 Sync","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046761","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588046761?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:01","pubTimestamp":1764766860,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X90EU:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NXL"],"gpt_icon":0},{"id":"2588046258","title":"Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 Sync™ Neurostimulation Console in Alzheimer’s Disease Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046258","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588046258?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:01","pubTimestamp":1764766860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X90EU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NXL"],"gpt_icon":0},{"id":"2588046796","title":"Nexalin Technology Inc: Intends to Incorporate FDA's Feedback From Q-Sub Meeting Into Its Final Pilot Study Protocol","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046796","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588046796?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:00","pubTimestamp":1764766855,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X8103:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NXL","BK4082"],"gpt_icon":0},{"id":"2588451053","title":"Nexalin Technology Hosts Live Investor Webinar Showcasing Mental Health Innovations","url":"https://stock-news.laohu8.com/highlight/detail?id=2588451053","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588451053?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:00","pubTimestamp":1764680436,"startTime":"0","endTime":"0","summary":"Nexalin Technology Inc. will host an exclusive live investor webinar and Q&A session on December 4, 2025, at 4:15 p.m. ET. The event, presented by RedChip Companies, will feature CEO Mark White discussing the company's innovative Deep Intracranial Frequency Stimulation  technology, recent clinical collaborations, and updates on Nexalin's Gen-3 HALO Clarity headset and Virtual Clinic model. The session will also highlight Nexalin's regulatory progress and growth strategy in the mental healthcare market, followed by a live Q&A with investors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original content used to generate this news brief via GlobeNewswire  on December 02, 2025, and is solely responsi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL2CSqVJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2210149790.SGD","LU2210150020.SGD","BK4082","BK4588","NXL","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","BK4585","IE00B64PRP62.GBP","NDAQ","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2587375914","title":"Nuix (ASX:NXL) delivers shareholders solid 39% CAGR over 3 years, surging 12% in the last week alone","url":"https://stock-news.laohu8.com/highlight/detail?id=2587375914","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587375914?lang=en_us&edition=fundamental","pubTime":"2025-11-29 06:45","pubTimestamp":1764369957,"startTime":"0","endTime":"0","summary":"It hasn't been the best quarter for Nuix Limited ( ASX:NXL ) shareholders, since the share price has fallen 26% in that...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice1-main-header/1585186668959","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice1-main-header/1585186668959"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/software/asx-nxl/nuix-shares/news/nuix-asxnxl-delivers-shareholders-solid-39-cagr-over-3-years","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/software/asx-nxl/nuix-shares/news/nuix-asxnxl-delivers-shareholders-solid-39-cagr-over-3-years","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NXL","BK4082","BK7016","NXL.AU"],"gpt_icon":0},{"id":"2584900892","title":"Morgan Stanley Sticks to Their Buy Rating for Nuix Ltd. (NXL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584900892","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584900892?lang=en_us&edition=fundamental","pubTime":"2025-11-20 13:55","pubTimestamp":1763618138,"startTime":"0","endTime":"0","summary":"In a report released today, Andrew McLeod from Morgan Stanley maintained a Buy rating on Nuix Ltd., with a price target of A$4.35. According to Tip...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-their-buy-rating-for-nuix-ltd-nxl-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-their-buy-rating-for-nuix-ltd-nxl-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NXL"],"gpt_icon":0},{"id":"2584538499","title":"Nexalin 15 mA Neurostimulation Device Shows Promise in Treating Gambling and Alcohol Use Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2584538499","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584538499?lang=en_us&edition=fundamental","pubTime":"2025-11-18 22:00","pubTimestamp":1763474412,"startTime":"0","endTime":"0","summary":"Nexalin Technology Inc. has announced the publication of an independent, peer-reviewed case report in The American Journal on Addictions evaluating the company's 15 mA neurostimulation device for treating gambling disorder with alcohol use comorbidity. The case was conducted at the Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, using Nexalin's non-invasive device, which delivered a 15 mA current at 77.5 Hz for 40 minutes per session. The study, registered on ClinicalTrials.gov , reported significant clinical improvement and sustained abstinence following treatment. The authors concluded that larger, controlled trials are warranted to further evaluate the device's efficacy in treating addiction comorbidities and other psychiatric disorders. These results have already been published and presented in the peer-reviewed journal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL6XzNhx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4082","NXL","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU0314104364.USD","NDAQ","BK4112","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210149790.SGD","IE00BKPKM429.USD","BK4585","BK4588"],"gpt_icon":0},{"id":"2583346036","title":"Nexalin Technology Faces Financial Risks Amid U.S.-China Trade Tensions","url":"https://stock-news.laohu8.com/highlight/detail?id=2583346036","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583346036?lang=en_us&edition=fundamental","pubTime":"2025-11-15 14:01","pubTimestamp":1763186494,"startTime":"0","endTime":"0","summary":"Nexalin Technology, Inc. (NXL) has disclosed a new risk, in the Regulation category. Nexalin Technology, Inc. faces significant business risks due ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nexalin-technology-faces-financial-risks-amid-u-s-china-trade-tensions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nexalin-technology-faces-financial-risks-amid-u-s-china-trade-tensions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NXL","BK4082"],"gpt_icon":0},{"id":"2583963905","title":"Nexalin Technology Secures Exclusive Distribution Agreement With Carmi Masha in Israel","url":"https://stock-news.laohu8.com/highlight/detail?id=2583963905","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583963905?lang=en_us&edition=fundamental","pubTime":"2025-11-13 22:15","pubTimestamp":1763043310,"startTime":"0","endTime":"0","summary":"Nexalin Technology Inc. has announced the appointment of Carmi Masha Technologies Ltd. as the exclusive distributor for its Gen-2 SYNC device in Israel. This follows the recent approval by the Israeli Ministry of Health, allowing commercial sales of the device for the treatment of mental health disorders such as insomnia, depression, and anxiety. Under the agreement, Carmi Masha Technologies will handle sales, marketing, clinical education, importation, registration, and distribution of the SYNC device throughout hospitals, clinics, and private treatment centers in Israel. The companies also plan to explore future applications for the technology in areas including PTSD, traumatic brain injury, and Alzheimer's disease.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL86SxVD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2210149790.SGD","LU2210150020.SGD","BK4082","BK4588","NXL","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","BK4585","IE00B64PRP62.GBP","NDAQ","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2581856870","title":"Nuix Limited (ASX:NXL) May Have Run Too Fast Too Soon With Recent 33% Price Plummet","url":"https://stock-news.laohu8.com/highlight/detail?id=2581856870","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581856870?lang=en_us&edition=fundamental","pubTime":"2025-11-08 06:54","pubTimestamp":1762556083,"startTime":"0","endTime":"0","summary":"Nuix Limited ( ASX:NXL ) shares have had a horrible month, losing 33% after a relatively good period beforehand. For...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice1-main-header/1585186668959","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice1-main-header/1585186668959"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/software/asx-nxl/nuix-shares/news/nuix-limited-asxnxl-may-have-run-too-fast-too-soon-with-rece","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/software/asx-nxl/nuix-shares/news/nuix-limited-asxnxl-may-have-run-too-fast-too-soon-with-rece","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4082","BK4567","IE00B5TLWC47.USD","IE00BYQQ9H92.USD","NXL","BK4588","FAST","BK4104","IE00BFXG0V08.USD","BK4585","BK7016","NXL.AU"],"gpt_icon":0},{"id":"2581786777","title":"BRIEF-Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by US FDA for the Treatment of Alzheimer’s Disease and Dementia","url":"https://stock-news.laohu8.com/highlight/detail?id=2581786777","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581786777?lang=en_us&edition=fundamental","pubTime":"2025-11-05 21:31","pubTimestamp":1762349489,"startTime":"0","endTime":"0","summary":"BRIEF-Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by US FDA for the Treatment of Alzheimer’s Disease and DementiaNov 5 (Reuters) - Nexalin Technology Inc NXL.O:NEXALIN TECHNOLOGY’S Q-SUB","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nFWN3WH1CG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","NXL"],"gpt_icon":0},{"id":"2579141531","title":"Nexalin Technology Wins Israeli Approval for Gen-2 SYNC Neurostimulation Device","url":"https://stock-news.laohu8.com/highlight/detail?id=2579141531","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579141531?lang=en_us&edition=fundamental","pubTime":"2025-10-30 20:30","pubTimestamp":1761827432,"startTime":"0","endTime":"0","summary":"Nexalin Technology Inc. has announced that its Gen-2 SYNC, a 15 mA neurostimulation device utilizing Deep Intracranial Frequency Stimulation , has received regulatory approval for sale in Israel from the Israeli Ministry of Health. This approval allows Nexalin to introduce its drug-free, non-invasive technology for the treatment of mental health disorders in Israel. The company stated that this milestone not only expands their presence in Israel but also enhances the global credibility of their platform, following previous approvals in China, Brazil, and Oman. No other organizations were mentioned as recipients of the regulatory approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexalin Technology Inc. published the original cont","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL6fpKQ9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NXL","BK4112","LU0314104364.USD","NDAQ","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4585","BK4588","LU2095319765.USD","LU2210150020.SGD","BK4082"],"gpt_icon":0},{"id":"2579149079","title":"Nexalin Technology Announces Regulatory Approval to Sell Gen 2 Sync, 15 Ma Neurostimulation Difs™ Device in Israel","url":"https://stock-news.laohu8.com/highlight/detail?id=2579149079","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579149079?lang=en_us&edition=fundamental","pubTime":"2025-10-30 20:30","pubTimestamp":1761827404,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nFWN3WB15N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NXL"],"gpt_icon":0},{"id":"2579483609","title":"Nuix (ASX:NXL) Valuation in Focus Following CEO Transition and Strategic Leadership Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2579483609","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579483609?lang=en_us&edition=fundamental","pubTime":"2025-10-29 03:29","pubTimestamp":1761679757,"startTime":"0","endTime":"0","summary":"Nuix (ASX:NXL) is drawing attention after CEO Jonathan Rubinsztein announced plans to step down at the end of October, with John Ruthven stepping in as interim CEO. Leadership transitions such as this can prompt fresh scrutiny from investors who are curious about the company’s next strategic moves.\nSee our latest analysis for Nuix.\nNuix shares have been on a turbulent ride lately, with the latest leadership change drawing even more focus. Despite a brief uptick, the 1-day share price return...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice1-main-header/1585186668959","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice1-main-header/1585186668959"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/software/asx-nxl/nuix-shares/news/nuix-asxnxl-valuation-in-focus-following-ceo-transition-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/software/asx-nxl/nuix-shares/news/nuix-asxnxl-valuation-in-focus-following-ceo-transition-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4082","NXL.AU","NXL","DCF","BK7016"],"gpt_icon":0},{"id":"2577287564","title":"Nexalin announces three studies published on Gen-2 Nexalin DIFS technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2577287564","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577287564?lang=en_us&edition=fundamental","pubTime":"2025-10-21 21:10","pubTimestamp":1761052234,"startTime":"0","endTime":"0","summary":"Nexalin Technology (NXL) announced that three independently published, peer-reviewed clinical studies, coupled with a growing body of internal data...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nexalin-announces-three-studies-published-on-gen-2-nexalin-difs-technology-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nexalin-announces-three-studies-published-on-gen-2-nexalin-difs-technology-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GEN","BK4097","NXL","BK4585","LU2286300806.USD","BK4588","BK4082"],"gpt_icon":0},{"id":"2577187344","title":"Nexalin's Difs™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer's and Dementia","url":"https://stock-news.laohu8.com/highlight/detail?id=2577187344","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577187344?lang=en_us&edition=fundamental","pubTime":"2025-10-21 21:08","pubTimestamp":1761052083,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nFWN3W220C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NXL","BK4082"],"gpt_icon":0},{"id":"2577739628","title":"Nexalin’s Difs™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2577739628","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577739628?lang=en_us&edition=fundamental","pubTime":"2025-10-21 21:02","pubTimestamp":1761051736,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nFWN3W12UH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","NXL"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nexalin.com","stockEarnings":[{"period":"1week","weight":-0.0607},{"period":"1month","weight":-0.2374},{"period":"3month","weight":-0.2449},{"period":"6month","weight":-0.2412},{"period":"1year","weight":-0.7071},{"period":"ytd","weight":-0.7209}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":0.0391},{"period":"3month","weight":0.0326},{"period":"6month","weight":0.128},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1685}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. In addition, it designs and develops Generation 2 and Generation 3, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, Alzheimer's disease, and dementia. The company is based in Houston, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.112523},{"month":2,"riseRate":0,"avgChangeRate":-0.115282},{"month":3,"riseRate":0.333333,"avgChangeRate":1.043912},{"month":4,"riseRate":0.666667,"avgChangeRate":0.017022},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.27991},{"month":6,"riseRate":0.666667,"avgChangeRate":0.427813},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.133577},{"month":8,"riseRate":0,"avgChangeRate":-0.230902},{"month":9,"riseRate":0,"avgChangeRate":-0.109096},{"month":10,"riseRate":0.75,"avgChangeRate":0.844573},{"month":11,"riseRate":0.75,"avgChangeRate":0.333914},{"month":12,"riseRate":0.25,"avgChangeRate":-0.317196}],"exchange":"NASDAQ","name":"Nexalin Technology, Inc.","nameEN":"Nexalin Technology, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nexalin Technology, Inc.(NXL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nexalin Technology, Inc.(NXL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nexalin Technology, Inc.,NXL,Nexalin Technology, Inc.股票,Nexalin Technology, Inc.股票老虎,Nexalin Technology, Inc.股票老虎国际,Nexalin Technology, Inc.行情,Nexalin Technology, Inc.股票行情,Nexalin Technology, Inc.股价,Nexalin Technology, Inc.股市,Nexalin Technology, Inc.股票价格,Nexalin Technology, Inc.股票交易,Nexalin Technology, Inc.股票购买,Nexalin Technology, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nexalin Technology, Inc.(NXL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nexalin Technology, Inc.(NXL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction